Savara (SVRA)

• Market cap: $1.02B
• 1 day: -3.88%
• 5 days: -6.77%
• 1 month: -10.31%
• 3 months: -23.34%
• 6 months: 42.12%
• Year to date: -12.06%
• 1 year: 73.43%
• 5 years: 155.67%
• 10 years: -72.21%
• Sector: Healthcare
• Industry: Biotechnology

About: Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Employees: 70